During this webinar, our experts will share insights on how our cutting-edge AAV transient transfection and producer cell line platforms can significantly accelerate your journey towards Investigational New Drug (IND) application success.

Current AAV manufacturing faces challenges such as low productivity, high costs, and supply chain issues. Lonza’s Xcite® AAV platforms, leveraging transient transfection and stable producer cell line (PCL) technologies, offer innovative solutions to these challenges.

Speakers: Suparna Sanyal, PhD, Head of Commercial Development Viral Vectors; Bingnan Gu, PhD, Head of R&D Viral Vectors

By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center